计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C302315-5mg |
5mg |
现货 ![]() |
| |
| C302315-10mg |
10mg |
现货 ![]() |
| |
| C302315-25mg |
25mg |
现货 ![]() |
| |
| C302315-50mg |
50mg |
现货 ![]() |
| |
| C302315-100mg |
100mg |
期货 ![]() |
|
| 英文别名 | (5-amino-1-(2-methyl-3H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone | CH5183284; Debio-1347 | GTPL9787 | EX-A1122 | NR9ZYH80Z8 | A901067 | AC-32960 | ZOLIGRATINIB [WHO-DD] | Debio 1347 | HY-19957 | Salicylic acid, {5-[[p-[(p-sulfopheny |
|---|---|
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | CH5183284 (Debio-1347) |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 成纤维细胞生长因子受体 1 抑制剂 |
| 产品介绍 |
Zoligratinib (Debio 1347) 是口服可用,选择性的 FGFR 抑制剂,抑制FGFR1,FGFR2和 FGFR3的IC50 值分别为9.3,7.6,22 and 290 nM |
| 纯度 | ≥99% |
| ALogP | 3.9 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488202056 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone |
| INCHI | 1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24) |
| InChi Key | BEMNJULZEQTDJY-UHFFFAOYSA-N |
| Smiles | CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N |
| Isomeric SMILES | CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N |
| 分子量 | 356.38 |
| Reaxy-Rn | 22632785 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=22632785&ln= |
| 分子量 | 356.400 g/mol |
|---|---|
| XLogP3 | 3.900 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 356.139 Da |
| 单同位素质量Monoisotopic Mass | 356.139 Da |
| 拓扑极表面积Topological Polar Surface Area | 105.000 Ų |
| 重原子数Heavy Atom Count | 27 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 573.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 | |
| 分析证书 | C302315 |
| 1. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T et al.. (2014) The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.. Mol Cancer Ther, 13 (11): (2547-58). [PMID:25169980] |
| 2. Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR et al.. (2019) A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.. Clin Cancer Res, 25 (9): (2699-2707). [PMID:30745300] |